Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
NCT01548573
Terminated
This study is designed to decrease toxicity associated with prior tandem transplant protocols by reducing the intensity of induction, consolidation and maintenance therapy, while increasing event-free survival by adding bortezomib (Velcade®), thalidomide, gemcitabine and carmustine to the transplant regimens to down-regulate the rescue of myeloma cells by the micro-environment and to prevent DNA repair post high-dose alkylating agent therapy. By reducing drug resistance, it is hoped that 3-year... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/19/2017
Locations: University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa
Conditions: Multiple Myeloma
Register for Updates
Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients
NCT02160301
Withdrawn
The study is a prospective, randomized, open-label comparison of a multimodal regimen and a standard, narcotic-based regimen for postoperative pain control in patients undergoing surgery for an operatively indicated, isolated extremity fracture. The investigators will be measuring pain levels, narcotic use, patient satisfaction, patient reported function, adverse events and fracture union. The investigators hypothesize that this multimodal regimen will lead to improved pain, less narcotic use an... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/17/2017
Locations: UNC Chapel Hill Hospital, Chapel Hill, North Carolina
Conditions: Post Operative Pain Control
Register for Updates
Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate
NCT00084864
Terminated
RATIONALE: Calcitriol and dexamethasone may slow the growth of prostate cancer cells. PURPOSE: This randomized phase II trial is studying how well giving calcitriol together with dexamethasone before radical prostatectomy works in treating patients with localized stage II or stage III adenocarcinoma (cancer) of the prostate.
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
05/11/2017
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Prostate Cancer
Register for Updates
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
NCT00381862
Completed
RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy. PURPOSE: This phase II trial is studying how well giving aprepitant together with palonosetron and dexamethasone works in preventing nausea and vomiting caused by chemotherapy in patients receiving chemotherapy for metastatic colorectal cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/07/2017
Locations: St. Josephs/Cander Hospital, Savannah, Georgia +5 locations
Conditions: Colorectal Cancer, Nausea and Vomiting
Register for Updates
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
NCT00248547
Completed
RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant. PURPOSE: This randomized clinical trial is studying aprepitant, ondansetron, and dexamethasone to see how well they work compared to placebo, ondansetron, and dexamethasone in preventing nausea and vomiting in patients who are undergoing a stem cell transplant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2017
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Cancer
Register for Updates
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
NCT00724568
Completed
This research study is evaluating an investigational combination of four drugs called Revlimid® (lenalidomide), Velcade® (bortezomib), Dexamethasone and Doxil® (RVDD) as a possible treatment for newly diagnosed multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2017
Locations: Emory University Hospital, Atlanta, Georgia +5 locations
Conditions: Multiple Myeloma
Register for Updates
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
NCT00150462
Completed
The purpose of this study is to test the safety and tolerability of carfilzomib at different dose levels on hematological cancers such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, or Waldenstrom's macroglobulinemia. Carfilzomib is a proteasome inhibitor, an enzyme responsible for degrading a wide variety of cellular proteins.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2017
Locations: Tower Cancer Research Foundation, Beverly Hills, California +4 locations
Conditions: Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
Register for Updates
Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
NCT00603447
Completed
To evaluate the safety and maximum tolerated dose (MTD) of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2017
Locations: Pacific Shores Medical Group, Long Beach, California +11 locations
Conditions: Relapsed Multiple Myeloma
Register for Updates
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
NCT01980589
Completed
The primary objective was to determine the maximum tolerated dose of carfilzomib given twice weekly in combination with cyclophosphamide and dexamethasone for patients with newly diagnosed multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2017
Locations: California Cancer Associates for Research and Excellence, Encinitas, California +8 locations
Conditions: Multiple Myeloma
Register for Updates
Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.
NCT01449682
Completed
To test the efficacy of a 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular function and recalcitrant macular edema associated with retinal vein occlusion following treatment with 2 or more prior intravitreal anti-VEGF drug injections.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2017
Locations: Retina Macula Institute, Torrance, California
Conditions: Retinal Vein Occlusion, Macular Edema
Register for Updates
Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis
NCT02309385
Completed
The purpose of this study is to determine the efficacy, safety, and tolerability of dexamethasone sodium phosphate Visulex (DSP-Visulex) after repeated-dose administration in patients with acute anterior uveitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2017
Locations: Massachusetts Eye Research and Surgery Institution (MERSI), Cambridge, Massachusetts +5 locations
Conditions: Non-Infectious Anterior Uveitis
Register for Updates
Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
NCT00074178
Completed
RATIONALE: Drugs used in chemotherapy, such as methotrexate, cyclophosphamide, etoposide phosphate, dexamethasone, and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Osmotic blood-brain barrier disruption uses certain drugs to open the blood vessels around the brain and allow anticancer substances to be delivered directly to the brain. Giving methotrexate, cyclophosphamide, and etoposide phosphate with osmotic blood-brain barrier disruption plu... Read More
Gender:
ALL
Ages:
Between 16 years and 75 years
Trial Updated:
04/19/2017
Locations: Oregon Health & Science University Cancer Institute, Portland, Oregon
Conditions: Lymphoma
Register for Updates